{"analyses":[{"ciLowerLimit":"0.54","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.85","estimateComment":"Stratified Cox proportional hazards model. Hazard ratio of nivolumab to investigator's choice therapy.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Hazard Ratio (HR)","paramValue":"0.68"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.68","upperLimit":"8.74","value":"7.72"},{"groupId":"OG001","lowerLimit":"4.04","upperLimit":"6.24","value":"5.06"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"240"},{"groupId":"OG001","value":"121"}],"units":"Participants"}],"description":"OS was defined as the time from randomization to the date of death from any cause. Participants were censored at the date they were last known to be alive and at the date of randomization if they were randomized but had no follow-up. Median OS time was calculated using Kaplan-Meier (KM) method.\n\nNote: This outcome measure represents an updated version of the primary endpoint to include additional data collection that has occurred after the primary completion date. (Assessments were made until 10-Sep-2021)","dispersionType":"95% Confidence Interval","groups":[{"description":"Nivolumab was provided at a dose of 3 milligrams/kilogram (mg/kg) using an intravenous (IV) solution for Injection every 2 weeks until disease progression.","id":"OG000","title":"Nivolumab 3mg/kg"},{"description":"Participants were provided a dose of Cetuximab intravenous (IV) solution for injection at a dose of 400 milligrams per square meter (mg/m\\^2) for the first dose followed that a doses of 250 mg/m\\^2 weekly until disease progression OR a Methotrexate intravenous (IV) solution for Injection at a dose of 40 or 60 mg/m\\^2 weekly until disease progression OR a Docetaxel intravenous (IV) solution for Injection at a dose of 30 or 40 mg/m\\^2 weekly until disease progression. The decision regarding which treatment the participant received was at the discretion of the investigator and referred to as Investigators Choice","id":"OG001","title":"Investigators Choice"}],"paramType":"MEDIAN","populationDescription":"All randomized participants","reportingStatus":"POSTED","timeFrame":"From date of randomization to date of death (Up to approximately 87 months)","title":"Overall Survival (OS) - Extended Collection","type":"POST_HOC","unitOfMeasure":"Months"}